4 Ways Concomitant Medications Can Complicate Your Clinical Trial

Concomitant medications (con-meds) wield significant influence over clinical trials, encompassing prescription drugs, over-the-counter remedies, and supplements taken alongside the investigational drug. Their presence impacts trial duration, costs, and participant eligibility and safety. Yet, despite their prominence, con-meds often evade thorough tracking and analysis in clinical studies.

A systematic review revealed that over half of trials impose medication-related exclusion criteria. Moreover, 85% of trials struggle to meet patient enrollment timelines, exacerbating the con-med challenge. Despite their common use among participants, con-meds' complexities and unreliable data hinder effective monitoring.

The industry grapples with outdated tracking methods and the complexity of con-med data, hampering accurate analysis. However, emerging electronic technologies promise streamlined data capture and analysis. Regulatory scrutiny is intensifying, urging comprehensive con-med evaluation in clinical study reports.

Take action to integrate con-med data for informed decisions by accessing the full article below and begin accelerating clinical research and cutting healthcare costs.